Pear Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Pear Therapeutics has a total shareholder equity of $30.6M and total debt of $27.4M, which brings its debt-to-equity ratio to 89.7%. Its total assets and total liabilities are $95.1M and $64.5M respectively.
Key information
89.7%
Debt to equity ratio
US$27.45m
Debt
| Interest coverage ratio | n/a |
| Cash | US$59.27m |
| Equity | US$30.59m |
| Total liabilities | US$64.54m |
| Total assets | US$95.13m |
Recent financial health updates
No updates
Recent updates
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch
Apr 17
Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue
Aug 18Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic
Aug 03Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction
May 21Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets
Apr 04Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy
Jan 10Financial Position Analysis
Short Term Liabilities: PEAR.Q's short term assets ($73.0M) exceed its short term liabilities ($49.4M).
Long Term Liabilities: PEAR.Q's short term assets ($73.0M) exceed its long term liabilities ($15.1M).
Debt to Equity History and Analysis
Debt Level: PEAR.Q has more cash than its total debt.
Reducing Debt: Insufficient data to determine if PEAR.Q's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if PEAR.Q has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PEAR.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.